Things never stand still for us

News

Telecoms update | Court orders submission of third party license and settlement agreements in FRAND case and imposes confidentiality regime; AASI granted ex parte

Recently, two interesting judgments were published in separate SEP/FRAND proceedings. The first decision pertains to a confidentiality regime and the second to an ex parte AASI. Confidentiality regime In the SEP/FRAND proceedings between Philips et al. vs. Xiaomi et al the District Court of The Hague (“DC”) decided on 14 July 2021 (decision published in
Read more ›

Chambers Global 2022 rankings: excellent results for BarentsKrans

We are excited to share the newest rankings of the Chambers Global Guide 2022. BarentsKrans once again received several honourable mentions for Corporate/ M&A, Dispute Resolution and Intellectual Property. Mentions Chambers Global 2022 The Chambers Global Guide ranks the top lawyers and law firms in over 200 jurisdictions across the world. The annual rankings are based
Read more ›

BarentsKrans advices sell-side in acquisition Eekels Pompen by Boels

BarentsKrans advised sell-side regarding the sale of Eekels Pompen B.V. and Eekels Materieelbeheer B.V. (in short: Eekels Pompen) to Boels-Gosink B.V., a subsidiary within the Boels group. Eekels Pompen has been offering specialised solutions in the area of pump installations for over a hundred years and contributes to national and international (pump) projects with more
Read more ›

Pharma update | Court of Appeal overturns ruling District Court in Astrazeneca v Menzis

In an earlier Pharma Update, we reported on the judgment of the District Court of The Hague of 14 October 2020 in which AstraZeneca AB (“AstraZeneca”) was ordered to pay damages to health insurer Menzis Zorgverzekeraar NV (“Menzis”) for having enforced a patent that was later invalidated against a generic company.   This judgment has now
Read more ›

Telecoms update | PI judge dismisses Ericsson’s anti-anti-suit injunction claim against Apple

On 16 December 2021 the PI Judge of the District Court of The Hague (“PI Judge”) rendered a judgment in PI proceedings initiated by Telefonaktiebolaget LM Ericsson (“Ericsson”) against Apple Retail Netherlands B.V., Apple Benelux B.V., Apple Inc., Apple Distribution International and Apple Sales International Ltd (“Apple et al.”). Ericsson is the patent proprietor of
Read more ›

BarentsKrans assisted VanderSat Holding on the sale of VanderSat to Planet Labs

BarentsKrans advised VanderSat Holding on the sale of specialized Dutch software developer VanderSat to Planet Labs, an American satellite company based in San Francisco. The transaction closed on 13 December 2021. Through this sale, VanderSat will be able to broaden its network and possibilities to use its science and technology on an even larger scale.
Read more ›

The Legal 500: Patent Litigation Country Comparative Guide

The BarentsKrans’ IP & Technology team contributed to The Legal 500: Patent Litigation Country Comparative Guide  by providing the chapter on patent litigation in The Netherlands. By means of a Q&A this guide describes the most important aspects of patent litigation in 27 countries worldwide. Each chapter provides information about the current issues affecting patent
Read more ›

BarentsKrans advised North Wall Capital on the acquisition growth financing of Dwarfs

BarentsKrans assisted the European special situations investor North Wall Capital in providing a loan facility in the amount of EUR 30 million to Dwarfs. Dwarfs will use this financing for its buy-and-build strategy with respect to e-commerce brands. As the first e-commerce scale-up in the Netherlands, Dwarfs focuses on acquiring and consolidating e-commerce brands that
Read more ›

Pharma update – 17 August 2021 | Provisions judge denies preliminary order to carve out indications from marketing authorisation adalimumab biosimilar

In his decision of 16 July 2021 (published 5 August 2021) the Provisions Judge of the District Court of Amsterdam denied a preliminary order claimed by AbbVie Biotechnology Ltd (“AbbVie”) against Alvotech HF, Alvotech Swiss AG and Stada Arzneimittel AG (“Stada”) (collectively: “Alvotech et al.”) to carve-out AbbVie’s patented indications prior to launching their biosimilar
Read more ›